Assessment of cardio-renal-hepatic function in patients with valvular heart disease: a multi-biomarker approach—the cardio-renal-hepatic score

Table 4 Associations of CRH score with mortality in clinically meaningful subgroups of patients

	Multivariable analysis
	Mortality under medical treatment	Mortality in patients with LVEF ≥ 50%	Mortality in patients with primary VHD
Total cohort
Adjusted HR (95%CI)	2.168 (1.946–2.416)	2.072 (1.806–2.376)	2.199 (1.876–2.578)
P value	< 0.001	< 0.001	< 0.001
AS^a
Adjusted HR (95%CI)	2.499 (0.922–6.778)	1.387 (0.776–2.481)	1.791 (1.018–3.148)
P value	0.072	0.270	0.043
AR^b
Adjusted HR (95%CI)	4.435 (2.781–7.072)	3.615 (2.110–6.193)	3.289 (2.111–5.127)
P value	< 0.001	< 0.001	< 0.001
MS^c
Adjusted HR (95%CI)	4.401 (1.155–16.778)	10.749 (3.134–36.867)	4.986 (2.069–12.016)
P value	0.030	< 0.001	< 0.001
MR
Adjusted HR (95%CI)	1.994 (1.601–2.483)	1.583 (1.112–2.253)	2.242 (1.445–3.477)
P value	< 0.001	0.011	< 0.001
TR
Adjusted HR (95%CI)	2.200 (1.758–2.751)	2.581 (1.975–3.371)	3.602 (2.158–6.013)
P value	< 0.001	< 0.001	< 0.001
MVHD
Adjusted HR (95%CI)	1.977 (1.642–2.380)	1.857 (1.449–2.378)	1.932 (1.485–2.514)
P value	< 0.001	< 0.001	< 0.001

Adjusted for age, sex, BMI, smoking status, hypertension, hyperlipidemia, diabetes, prior myocardial infarction, cardiomyopathy, atrial fibrillation or flutter, chronic lung disease, NYHA functional class, hemoglobin, LA, LVEDD, LVEF, pulmonary hypertension, severity of VHD, and valvular intervention
CRH cardio-renal-hepatic, LVEF left ventricular ejection fraction, VHD valvular heart disease, AS aortic stenosis, AR aortic regurgitation, MS mitral stenosis, MR mitral regurgitation, TR tricuspid regurgitation, MVHD multiple valvular heart disease, BMI body mass index, NYHA New York Heart Association, LA left atrial end-diastolic dimension, LVEDD left ventricular end-diastolic dimension, HR hazard ratio, CI confidence interval
^aFor AS patients under medical treatment, cardiomyopathy was not adjusted because no death occurred in patients with cardiomyopathy. For AS patients with LVEF ≥ 50%, cardiomyopathy and CLD were not adjusted because no death occurred in patients with cardiomyopathy or CLD
^bFor AR patients with LVEF ≥ 50%, cardiomyopathy was not adjusted because no death occurred in patients with cardiomyopathy
^cAdjusted for age and sex

ISSN: 1741-7015